|
| 36370152 | Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis. | Endocrine | 2023 |
| 36370152 | Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis. | Endocrine | 2023 |
| 37944134 | Standardized In Vitro Models of Human Adipose Tissue Reveal Metabolic Flexibility in Brown Adipocyte Thermogenesis. | Endocrinology | 2023 |
| 37284613 | Long-Term Outcomes of Parathyroid Autografts in Primary Hyperparathyroidism. | J Endocr Soc | 2023 |
| 37011647 | Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. | Lancet Diabetes Endocrinol | 2023 |
| 37450696 | Parathyroidectomy and the Risk of Major Cerebrovascular and Cardiovascular Events in the Elderly. | Ann Surg | 2023 |
| 37307230 | Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression. | J Clin Endocrinol Metab | 2023 |
| 37296836 | Preclinical Models of Adrenocortical Cancer. | Cancers (Basel) | 2023 |
| 36925188 | Multiple Endocrine Neoplasia Type 1 Syndrome Pancreatic Neuroendocrine Tumor Genotype/Phenotype: Is There Any Advance on Predicting or Preventing? | Surg Oncol Clin N Am | 2023 |
| 37944134 | Standardized In Vitro Models of Human Adipose Tissue Reveal Metabolic Flexibility in Brown Adipocyte Thermogenesis. | Endocrinology | 2023 |
| 37450696 | Parathyroidectomy and the Risk of Major Cerebrovascular and Cardiovascular Events in the Elderly. | Ann Surg | 2023 |
| 37284613 | Long-Term Outcomes of Parathyroid Autografts in Primary Hyperparathyroidism. | J Endocr Soc | 2023 |
| 37011647 | Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. | Lancet Diabetes Endocrinol | 2023 |
| 37307230 | Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression. | J Clin Endocrinol Metab | 2023 |
| 37296836 | Preclinical Models of Adrenocortical Cancer. | Cancers (Basel) | 2023 |
| 36925188 | Multiple Endocrine Neoplasia Type 1 Syndrome Pancreatic Neuroendocrine Tumor Genotype/Phenotype: Is There Any Advance on Predicting or Preventing? | Surg Oncol Clin N Am | 2023 |
| 34415331 | Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma. | J Natl Cancer Inst | 2022 |
| 36111275 | Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors. | J Endocr Soc | 2022 |
| 36358665 | Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer. | Cancers (Basel) | 2022 |
| 36151566 | Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer. | J Exp Clin Cancer Res | 2022 |
| 36010880 | Performances of Functional and Anatomic Imaging Modalities in <i>Succinate Dehydrogenase A-</i>Related Metastatic Pheochromocytoma and Paraganglioma. | Cancers (Basel) | 2022 |
| 36077665 | A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. | Cancers (Basel) | 2022 |
| 35999087 | Predictors of post-operative pancreatic fistula formation in pancreatic neuroendocrine tumors: A national surgical quality improvement program analysis. | Am J Surg | 2022 |
| 35861986 | Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis. | Eur J Endocrinol | 2022 |
| 35295984 | Editorial: Molecular Mechanisms in Cancer Endocrinology With Clinical Implications. | Front Endocrinol (Lausanne) | 2022 |
| 34735022 | Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. | Cancer | 2022 |
| 34668970 | "Cutting the Support" to Improve Treatment Efficacy in Thyroid Cancer by Targeting Tumor Microenvironment. | J Clin Endocrinol Metab | 2022 |
| 34431366 | Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using <sup>68</sup>Ga-DOTATATE, FDG, <sup>18</sup>F-FDOPA, and <sup>18</sup>F-FDA). | AJR Am J Roentgenol | 2022 |
| 34536193 | A long noncoding RNA-microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. | Endocrine | 2022 |
| 34415331 | Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma. | J Natl Cancer Inst | 2022 |
| 35861986 | Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis. | Eur J Endocrinol | 2022 |
| 36111275 | Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors. | J Endocr Soc | 2022 |
| 35999087 | Predictors of post-operative pancreatic fistula formation in pancreatic neuroendocrine tumors: A national surgical quality improvement program analysis. | Am J Surg | 2022 |
| 36358665 | Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer. | Cancers (Basel) | 2022 |
| 36010880 | Performances of Functional and Anatomic Imaging Modalities in <i>Succinate Dehydrogenase A-</i>Related Metastatic Pheochromocytoma and Paraganglioma. | Cancers (Basel) | 2022 |
| 36151566 | Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer. | J Exp Clin Cancer Res | 2022 |
| 36077665 | A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. | Cancers (Basel) | 2022 |
| 35295984 | Editorial: Molecular Mechanisms in Cancer Endocrinology With Clinical Implications. | Front Endocrinol (Lausanne) | 2022 |
| 34735022 | Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. | Cancer | 2022 |
| 34668970 | "Cutting the Support" to Improve Treatment Efficacy in Thyroid Cancer by Targeting Tumor Microenvironment. | J Clin Endocrinol Metab | 2022 |
| 34431366 | Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using <sup>68</sup>Ga-DOTATATE, FDG, <sup>18</sup>F-FDOPA, and <sup>18</sup>F-FDA). | AJR Am J Roentgenol | 2022 |
| 34536193 | A long noncoding RNA-microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. | Endocrine | 2022 |
| 32943182 | Pancreatic insufficiency following pancreatectomy: Does underlying tumor syndrome confer a greater risk? | Am J Surg | 2021 |
| 33644619 | First Somatic <i>PRKAR1A</i> Defect Associated With Mosaicism for Another <i>PRKAR1A</i> Mutation in a Patient With Cushing Syndrome. | J Endocr Soc | 2021 |
| 33732213 | Current Status and Future Targeted Therapy in Adrenocortical Cancer. | Front Endocrinol (Lausanne) | 2021 |
| 33939050 | Contralateral Suppression Index Does Not Predict Clinical Cure in Patients Undergoing Surgery for Primary Aldosteronism. | Ann Surg Oncol | 2021 |
| 33986746 | The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment. | Front Immunol | 2021 |
| 33933279 | The impact of level II evidence on surgical practice: Dual agent bowel prep for elective colorectal surgery. | Surgery | 2021 |
| 33721134 | ASO Author Reflections: Predicting Postoperative Resolution of Hypertension in Primary Hyperaldosteronism. | Ann Surg Oncol | 2021 |
| 34318891 | A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. | J Clin Endocrinol Metab | 2021 |